• Vittorio Simeon, Katia Todoerti, Francesco La Rocca, Antonella Caivano, Stefania Trino, Marta Lionetti, Luca Agnelli, Luciana De Luca, Ilaria Laurenzana, Antonino Neri, and Pellegrino Musto.
• Laboratory of Pre-Clinical and Translational Research, Reference Cancer Center of Basilicata, Scientific Institute of Hospitalization and Treatment, Rionero in Vulture 85028, Italy. Vittorio.simeon@crob.it.
• Int J Mol Sci. 2015 Jul 30; 16 (8): 17514-34.

AbstractPrimary plasma cell leukemia (pPCL) is a rare and aggressive variant of multiple myeloma (MM) which may represent a valid model for high-risk MM. This disease is associated with a very poor prognosis, and unfortunately, it has not significantly improved during the last three decades. New high-throughput technologies have allowed a better understanding of the molecular basis of this disease and moved toward risk stratification, providing insights for targeted therapy studies. This knowledge, added to the pharmacogenetic profile of new and old agents in the analysis of efficacy and safety, could contribute to help clinical decisions move toward a precision medicine and a better clinical outcome for these patients. In this review, we describe the available literature concerning the genomic characterization and pharmacogenetics of plasma cell leukemia (PCL).

18 keywords...

hide…